P38α mitogen-activated protein kinase inhibitors, a patent review (2005 2011)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 12, 2011, Pages 1843-1866

  Fischer, Stefan ^a   Koeberle, Solveigh C ^b   Laufer, Stefan A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

(TNF) ; Allosteric inhibitor; Asthma; BIRB 796; Competitive inhibitor; COPD; Cytokine; DFG out; GW 856553; Inflammatory diseases; Intracellular target; Kinase; Neuropathic pain; P38 MAP kinase; PH 797804; Pulmonary diseases; Rheumatoid arthritis; SB 681323; SCIO 469; VX 745

Indexed keywords

5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ACR 20; ARRY 371797; ASPARTIC ACID; BMS 582949; BORTEZOMIB; DILMAPIMOD; DORAMAPIMOD; GLUTAMINE; GLYCINE; IMIDAZOLE DERIVATIVE; LOSMAPIMOD; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA INHIBITOR; PAMAPIMOD; PH 797804; PYRIDINYLIMIDAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; TALMAPIMOD; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VX 702;

ALZHEIMER DISEASE; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; BINDING SITE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CRYSTAL STRUCTURE; CYCLIZATION; CYTOKINE RELEASE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; IC 50; KNEE PAIN; MELANOMA; NEUROPATHIC PAIN; PATENT; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN INFECTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG DESIGN; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 81855211127     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.636737     Document Type: Review

References (200)

1. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46
2. Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008;67:909-16
3. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009;60:317-20
4. Hammaker D, Firestein GS. "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis 2010;69(Suppl 1):i77-82
5. Korb A, Tohidast-Akrad M, Cetin E, et al. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum 2006;54:2745-56
6. CAIR Biosciences GMBH. Method for subgroup analysis in subjects having or being suspected of having inflammatory disease, use of anti-p38mapk antibodies, kits and their use. EP1909102; 2008
7. Available from: www.clinicaltrialsfeeds.org 2011
8. Available from: www.ambitbio.com 2011
9. Available from: www.proqinase.com 2011
10. Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 2005;12:2979-94
11. Backes AC, Zech B, Felber B, et al. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opin Drug Discov 2008;3:1427-49
12. Backes AC, Zech B, Felber B, et al. Small-molceule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition. Expert Opin Drug Discov 2008;12:1409-25
13. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36
14. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32
15. Fitzgerald CE, Patel SB, Becker JW, et al. Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat Struct Biol 2003;10:764-9
16. Takeda Pharmaceutical. Medicinal compositions. WO2002100433; 2002
17. Takeda Pharmaceutical. Novel solid dispersion and manufacturing method there of WO2006006691; 2006
18. Miwatashi S, Arikawa Y, Kotani E, et al. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)- 1, 3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem 2005;48:5966-79
19. Takeda Pharmaceutical. Condensed imidazole compound and use there of EP1832588; 2007
20. Takeda Pharmaceutical. Fused imidazole compound and use there of WO2008133192; 2008
21. Takeda Pharmaceutical. Fused heterocyclic compound. WO2011021678; 2011
22. Cadila Healthcare Ltd. Sulfoximine derivatives as p38 map kinase inhibitors. WO2007077574; 2007
23. Vertex Pharma. Inhibitors of p38. WO9964400; 1999
24. Karcher SC, Laufer SA. Successful structure-based design of recent p38 MAP kinase inhibitors. Curr Top Med Chem 2009;9:655-76
25. Vertex Pharma. Pyridine derivatives as inhibitors ofP38. WO0214281; 2002
26. Vertex Pharma. Inhibitors of p38. US7205305; 2007
27. Vertex Pharma. Inhibitors of p38. AU2007200477; 2008
28. Vertex Pharma. Inhibitors of p38. US7423049; 2008
29. Vertex Pharma. Pyridine derivatives as inhibitors ofp38. AU2007249154; 2008
30. Vertex Pharma. Inhibitors of p38. US7598277; 2009
31. Vertex Pharma. Inhibitors ofp38. US2009075981; 2009
32. Vertex Pharma. Processes for producing phenyl-6-(1-(phenyl)ureido) nicotinamides). WO2010093890; 2010
33. Vertex Pharma. Inhibitors of p38. US7951809; 2011
34. Vertex Pharma. Inhibitors of p38. US7919513; 2011
35. Vertex Pharma. Compositions and methods for treating rheumatoid arthritis. WO2007103468; 2007
36. Vertex Pharma. Isoquinoline inhibitors ofP38. EP1414455; 2004
37. Vertex Pharma. Inhibitors of p38. US7151101; 2006
38. Natarajan SR, Wisnoski DD, Singh SB, et al. p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d] pyrimidone scaffold. Bioorg Med Chem Lett 2003;13:273-6
39. Natarajan SR, Doherty JB. P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes. Curr Top Med Chem 2005;5:987-1003
40. Stelmach JE, Liu L, Patel SB, et al. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 2003;13:277-80
41. Liu L, Stelmach JE, Natarajan SR, et al. SAR of 3,4-dihydropyrido[3,2-d] pyrimidone p38 inhibitors. Bioorg Med Chem Lett 2003;13:3979-82
42. Merck Sharp & Dohme. Treatment for Alzheimer's disease and related conditions. WO2005058308; 2005
43. Hunt JA, Kallashi F, Ruzek RD, et al. p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones. Bioorg Med Chem Lett 2003;13:467-70
44. Bao J, Hunt JA, Miao S, et al. p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones. Bioorg Med Chem Lett 2006;16:64-8
45. Chen MH, Fitzgerald P, Singh SB, et al. Synthesis and biological activity of quinolinone and dihydroquinolinone p38 MAP kinase inhibitors. Bioorg Med Chem Lett 2008;18:2222-6
46. Tynebor RM, Chen MH, Natarajan SR et al. Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors. Bioorg Med Chem Lett 2010;20:2765-9
47. Merck & Co., Inc. [US]. P38 kinase inhibiting agents. WO2007067478; 2007
48. Merck & Co., Inc. [US]. Heterobicyclic compounds useful as P38 kinase inhibiting agents. WO2007021710; 2007
49. Merck Sharp & Dohme. P38 kinase inhibiting agents. WO2010129208; 2010
50. Tynebor RM, Chen MH, Natarajan SR et al. Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1. Bioorg Med Chem Lett 2011;21:411-16
51. Merck & Co., Inc. [US]. Pyrrolo [2, 3-C] pyridine derivatives as P38 kinase inhibiting agents. WO2009152072; 2009
52. Patel SB, Cameron PM, O'Keefe SJ, et al. The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha. Acta Crystallogr D Biol Crystallogr 2009;65:777-85
53. Trejo A, Arzeno H, Browner M, et al. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase. J Med Chem 2003;46:4702-13
54. F. Hoffmann-La Roche. Fused derivatives of pyrazole. WO2005085249; 2005
55. F. Hoffmann-La Roche. Indazole derivatives and pharmaceutical compositions containing them. WO2005085206; 2005
56. F. Hoffmann-La Roche. P38 map kinase inhibitors and methods for using the same. WO2007023111; 2007
57. F. Hoffmann-La Roche. P38 map kinase inhibitors and methods for using the same. WO2007023110; 2007
58. F. Hoffmann-La Roche. P38 map kinase inhibitors and methods for using the same. WO2007023115; 2007
59. F. Hoffmann-La Roche. Fused pyrazole as p38 map kinase inhibitors. WO2007023105; 2007
60. F. Hoffmann-La Roche. P38 map kinase inhibitors and methods for using the same. WO2007023114; 2007
61. F. Hoffmann-La Roche. Kinase Inhibitors and methods for using the same. WO2008104473; 2008
62. F. Hoffmann-La Roche. Pyrazolo [3, 4 -D] pyrimidine p38 map kinase inhibitors. WO2008074676; 2008
63. Roche Palo Alto LLC. Methods of inhibiting p38 with substituted bicyclic pyrimidines. US7449472; 2008
64. Roche Palo Alto LLC. p38 map kinase inhibitors and methods for using the same. US7517901; 2009
65. Goldstein DM, Gabriel T. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem 2005;5:1017-29
66. F.Hoffmann-La Roche. Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones. WO2005047284; 2005
67. F. Hoffmann-La Roche. Substituted 6-phenyl-pyrido [2,3-D] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same. WO2008055842; 2008
68. Roche Palo Alto LLC. Imidazo-substituted compounds as p38 kinase inhibitors. US7081462; 2006
69. Roche Palo Alto LLC. Imidazo-substituted compounds as P38 kinase inhibitors. US7285561; 2007
70. Roche Palo Alto LLC. Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones. US7348331; 2008
71. Hill RJ, Dabbagh K, Phippard D, et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 2008;327:610-19
72. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:335-44
73. Dambach DM. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 2005;5:929-39
74. Mavunkel BJ, Chakravarty S, Perumattam JJ, et al. Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue. Bioorg Med Chem Lett 2003;13:3087-90
75. Scios, Inc. Indole-type inhibitors of p38 kinase. US6890938; 2005
76. Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase. US6867209; 2005
77. Scios, Inc. Inhibitors of p38 kinase. US7291613; 2007
78. Scios, Inc. Pharmaceutical formulations of an indole-type derivative and related methods ofuse. WO2008024391; 2008
79. Scios, Inc. Indole-type derivatives as inhibitors of P38 kinase. US7488744; 2009
80. Scios, Inc. Azaindole derivatives as inhibitors of P38 kinase. WO2006112828; 2006
81. Tan X, Tester RW, Luedtke GR, et al. Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles. Bioorg Med Chem Lett 2010;20:828-31
82. Navas TA, Nguyen AN, Hideshima T, et al. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006;20:1017-27
83. Scios, Inc. Method oftreating myelodysplastic syndromes. US2006258582; 2006
84. Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition. US2006052390; 2006
85. Scios, Inc. Treatment ofmultiple myeloma by inhibition of p38 MAP kinase. US2006079461; 2006
86. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008;47:409-14
87. Mavunkel BJ, Perumattam JJ, Tan X, et al. Piperidine-based heterocyclic oxalyl amides as potent p38 alpha MAP kinase inhibitors. Bioorg Med Chem Lett 2010;20:1059-62
88. Luedtke GR, Schinzel K, Tan X, et al. Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules. Bioorg Med Chem Lett 2010;20:2556-9
89. Scios, Inc. Heterocyclic amides and sulfonamides. WO2005033072; 2005
90. Scios, Inc. Quinazoline derivatives as medicaments. US2005220784; 2005
91. Murali Dhar TG, Wrobleski ST, Lin S, et al. Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds. Bioorg Med Chem Lett 2007;17:5019-24
92. Squibb Bristol Myers Co. Heterobicyclic compounds useful as kinase inhibitors. US7943617; 2011
93. Liu C, Lin J, Pitt S, et al. Benzothiazole based inhibitors of p38alpha MAP kinase. Bioorg Med Chem Lett 2008;18:1874-9
94. Squibb Bristol Myers Co. Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors. WO2007016392; 2007
95. Squibb Bristol Myers Co. Phenyl-substituted pyrimidine compounds useful as kinase inhibitors. WO2006084017; 2006
96. Squibb Bristol Myers Co. Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors. WO2009155388; 2009
97. Squibb Bristol Myers Co. Triazolopyridine compounds useful as kinase inhibitors. WO2009155389; 2009
98. Leftheris K, Ahmed G, Chan R, et al. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase. J Med Chem 2004;47:6283-91
99. Squibb Bristol Myers Co. N-heterocyclic inhibitors of TNF-alpha expression. US7479495; 2009
100. Lin TH, Metzger A, Diller DJ, et al. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors. J Pharmacol Exp Ther 2006;318:495-502
101. Liu C, Wrobleski ST, Lin J, et al. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase. J Med Chem 2005;48:6261-70
102. Squibb Bristol Myers Co. N-heterocyclic inhibitors of TNF-alpha expression. US7253174; 2007
103. Squibb Bristol Myers Co. N-heterocyclic inhibitors of tnf-alpha expression. US2008015185; 2008
104. Das J, Moquin RV, Pitt S, et al. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. Bioorg Med Chem Lett 2008;18:2652-7
105. Squibb Bristol Myers Co. Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors. WO2006020904; 2006
106. Squibb Bristol Myers Co. Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors. US2006035886; 2006
107. Squibb Bristol Myers Co. Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl -N-propylpyrrolo[2,1-f] [1,2,4]triazine-6-carboxamide and novel stable forms producedtherein. US2009312331; 2009
108. Squibb Bristol Myers Co. Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl] amino]-5-methyl-N- propylpyrrolo[2,1-F][1,2,4]triazine-6-carboxamide and novel stable forms produced therein. EP1874778; 2009
109. Squibb Bristol Myers Co. Tablet formulation for P38 inhibitor and method. WO2010120963; 2010
110. Hynes J Jr, Dyckman AJ, Lin S, et al. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1, 2,4] triazine p38alpha mitogen-activated protein kinase inhibitors. J Med Chem 2008;51:4-16
111. Liu C, Lin J, Wrobleski ST, et al. Discovery of 4-(5- (cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2, 4]triazine-6-carboxamide (BMS-582949), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases. J Med Chem 2010;53:6629-39
112. Sack JS, Kish KF, Pokross M, et al. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase. Acta Crystallogr D Biol Crystallogr 2008;D64:705-10
113. Squibb Bristol Myers Co. Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors. WO2005077945; 2005
114. Squibb Bristol Myers Co. Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors. US2009149650; 2009
115. Squibb Bristol Myers Co. Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors. US7491725; 2009
116. Hynes J Jr, Wu H, Pitt S, et al. The discovery of (R)-2-(sec-butylamino)- N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor. Bioorg Med Chem Lett 2008;18:1762-7
117. Boehringer Ingelheim Pharma. Methods of treating copd and pulmonary hypertension. WO2005018624; 2005
118. Boehringer Ingelheim Pharma. Methods of treating COPD and pulmonary hypertension. US2005148555; 2005
119. Boehringer Ingelheim Pharma. New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders. WO2006015775; 2006
120. Boehringer Ingelheim Pharma. New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders. WO2008049842; 2008
121. Cogan DA, Aungst R, Breinlinger EC, et al. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 2008;18:3251-5
122. Boehringer Ingelheim Pharma. 7-(Piperazine-1-ymethyl)-1H-indole-2- carboxylic acid (phenyl)-amide derivatives and allied compounds as P38 map kinase inhibitors for the treatment of respiratory diseases. WO2010026096; 2010
123. Goldberg DR, Hao MH, Qian KC, et al. Discovery and optimization of p38 inhibitors via computer-assisted drug design. J Med Chem 2007;50:4016-26
124. Bayer Pharmaceuticals Corp. Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas. EP1616865; 2006
125. Bayer Healthcare LLC. [omega]-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors. US7897623; 2011
126. Lilly Co. Eli. Pyrazole-isoquinoline urea derivatives as P38 kinase inhibitors. WO2007053346; 2007
127. Pulmagen Therapeutics Inflamma. Pyridylurea derivatives and their therapeutic use. WO2010131030; 2010
128. Pulmagen Therapeutics Inflamma. Triazolopyridine derivatives as P38 map kinase inhibitors. WO2010094956; 2010
129. Pulmagen Therapeutics Inflamma. Pyrimidopyridazine derivatives useful as P38 mapk inhibitors. WO2010094955; 2010
130. Pulmagen Therapeutics Inflamma. New combinations for the treatment of asthma. WO2011012897; 2010
131. Pharmacia & Upjohn Co. LLC. Novel triazolopyridine compounds for the treatment of inflammation. WO2006018727; 2006
132. Pharmacia & Upjohn Co. LLC. Novel triazolopyridine compounds. WO2006018735; 2006
133. Pfizer Ltd. Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors. WO2006018718; 2006
134. Pfizer Ltd. Triazolopyridine compounds. WO2007091152; 2007
135. Jerome KD, Rucker PV, Xing L, et al. Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition. Bioorg Med Chem Lett 2010;20:469-73
136. Xing L, Shieh HS, Selness SR, et al. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804. Biochemistry 2009;48:6402-11
137. Pharmacia & Upjohn Co. LLC. Crystalline forms of3-[5-chloro-4-[(2,4- difluorobenzyl) oxy]-6-oxopyrimidin-1 (6H)-YL]-N-(2-hydroxyethyl)-4- methylbenzamide. WO2006040649; 2006
138. Pharmacia Corp. Diaryl substituted pyridinones. US2006211694; 2006
139. Pharmacia Corp. Substituted pyrimidinones. US7795271; 2010
140. Pfizer Prod, Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives. WO2007091176; 2007
141. Pfizer Prod, Inc. Methods oftreating acute inflammation in animals with p38 map kinase inhibitors. WO2005060967; 2005
142. Walker JK, Selness SR, Devraj RV, et al. Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. Bioorg Med Chem Lett 2010;20:2634-8
143. Angell RM, Angell TD, Bamborough P, et al. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett 2008;18:4433-7
144. Glaxo Group Ltd. Novel compounds. WO2006110298; 2006
145. Glaxo Group Ltd. Novel compounds. WO2006104915; 2006
146. Glaxo Group Ltd. Novel compounds. WO2006104889; 2006
147. Glaxo Group Ltd. Novel compounds. WO2007147109; 2007
148. Glaxo Group Ltd. Novel compounds. WO2007147104; 2007
149. Glaxo Group Ltd. Novel compounds. WO2007147103; 2007
150. Glaxo Group Ltd. Compounds. US7674789; 2010
151. Glaxo Group Ltd. Compounds. US7678801; 2011
152. Anand P, Shenoy R, Palmer JE, et al. Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain 2011;15(12):1040-8
153. Glaxo Group Ltd. Novel process and formulations. WO2007059500; 2007
154. Smithkline Beecham Corp. 3- aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as P38 kinase inhibitors. WO2005014550; 2005
155. Aston NM, Bamborough P, Buckton JB, et al. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J Med Chem 2009;52:6257-69
156. Amgen, Inc. Quinazoline and pyridopyrimidine derivatives as P38 kinase inhibitors. WO2008011032; 2008
157. Pettus LH, Wurz RP. Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008. Curr Top Med Chem 2008;8:1452-67
158. Herberich B, Cao GQ, Chakrabarti PP, et al. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold. J Med Chem 2008;51:6271-9
159. Amgen, Inc. Phthalazine compounds as p38 map kinase modulators and methods of use there of. WO2010042649; 2010
160. Amgen, Inc. Pyrido[3,2-d]pyridazine-2 (1H)-one compounds as P38 modulators and methods of use there of WO2010025202; 2010
161. Amgen, Inc. Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use there of WO2010042646; 2010
162. Amgen, Inc. Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases. WO2010025201; 2010
163. Pettus LH, Xu S, Cao GQ, et al. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase. J Med Chem 2008;51:6280-92
164. Amgen, Inc., amg. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators, process for their preparation, and their pharmaceutical use. WO2008136948; 2008
165. Amgen, Inc. Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use. WO2008137176; 2008
166. Amgen, Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof. WO2008045393; 2008
167. Amgen, Inc. Pyrazolo-pyrazinone compounds and methods of use there of WO2009117156; 2009
168. Amgen, Inc. Pyrazolo-pyridinone derivatives and methods of use. WO2009055033; 2009
169. Amgen, Inc. Triazole fused heteroaryl compounds as P38 kinase inhibitors. WO2009038784; 2009
170. Pettus LH, Wurz RP, Xu S, et al. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase. J Med Chem 2010;53:2973-85
171. Almirall Lab. New pyridin-3-amine derivatives. WO2007096072; 2007
172. Lumeras W, Caturla F, Vidal L, et al. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase. J Med Chem 2009;52:5531-45
173. Almirall Lab. 1, 7-naphthyridine derivatives as P38 map kinase inhibitors. WO2008017461; 2008
174. Almirall Lab. New 4,8-diphenyl-polyazanaphthalene derivatives. WO2008131922; 2008
175. Almirall Lab. New 3-([1,2,4]triazolo[4,3-A]pyridin-7-YL)benzamide derivatives. WO2008107125; 2008
176. Almirall Lab. New substituted spiro [cycloalkyl-1,3'-indol]-2'(1'H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors. WO2009124692; 2009
177. Almirall Lab. New substituted indolin-2-one derivatives and their use as P39 mitogen-activated kinase inhibitors. WO2009132774; 2009
178. Almirall Lab. New 7-phenyl-[1,2,4] triazolo[4,3-A]pyridin-3(2H)-one derivatives. WO2011057757; 2011
179. Revesz L, Blum E, Di Padova FE, et al. Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity. Bioorg Med Chem Lett 2006;16:262-6
180. Triad Therapeutics, Inc. Bicyclic heterocyclic P-38 kinase inhibitors. WO2005063766; 2005
181. Triad Therapeutics, Inc. 5-Membered heterocycle-based P38 kinase inhibitors. WO2005009973; 2005
182. Triad Therapeutics, Inc. p-38 kinase inhibitors. WO2005012241; 2005
183. Triad Therapeutics, Inc. 5-membered heterocycle-based P-38 inhibitors. WO2005000298; 2005
184. Novartis AG. P-38 inhibitors. US7652044; 2010
185. Novartis AG. 5-membered heterocycle-based p38 kinase inhibitors. US7863314; 2011
186. Revesz L, Blum E, Di Padova FE, et al. SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity. Bioorg Med Chem Lett 2004;14:3601-5
187. Laufer SA, Ahrens GM, Karcher SC, et al. Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e] oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors. J Med Chem 2006;49:7912-15
188. Merckle GMBH. Dibenzocycloheptane compounds and pharmaceuticals containing these compounds. WO2006120010; 2006
189. Ottosen ER, Sorensen MD, Bjorkling F, et al. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem 2003;46:5651-62
190. CAIR Biosciences GMBH. Dibenzocycloheptanone derivatives and pharmaceutical agents containing said compounds. WO2010040843; 2010
191. Arqule, Inc. 1,4-Disubstituted naphtalenes as inhibitors of P38 map kinase. WO2006010082; 2006
192. Arqule, Inc. Synthesis ofimidazooxazole and imidazothiazole inhibitors of P38 map kinase. WO2006044869; 2006
193. Array Biopharma, Inc. 38 inhibitors and methods of use there of WO2006122230; 2006
194. Array Biopharma, Inc. P38 inhibitors and methods of use there of WO2007126871; 2007
195. Uriachy Compania SAJ. Heterocyclic compounds. WO2006013095; 2006
196. Uriachy Compania SAJ. Bicyclic derivatives as P38 inhibitors. WO2007000340; 2007
197. Uriachy Compania SAJ. Bicyclic derivatives as P38 kinase inhibitors. WO2007000339; 2007
198. Uriachy Compania SAJ. Bicyclic derivatives as P38 kinase inhibitors. WO2007000337; 2007
199. Palau Pharma SA. Pyrazoloisoquinoline derivatives. WO2007060198; 2007
200. Dominguez C, Tamayo N, Zhang D. p38 Inhibitors: beyond pyridinylimidazoles. Expert Opin Ther Patents 2005;15:801-16